← Back to Search

Platelet Rich Plasma

PRP Therapy for Infertility (PIER Trial)

N/A
Recruiting
Research Sponsored by Reproductive Medicine Associates of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 9 weeks gestational age
Awards & highlights

Summary

This trial will test whether a PRP infusion into the uterus can help infertile women with thin endometrium conceive via IVF.

Who is the study for?
This trial is for women who've had at least two unsuccessful frozen embryo transfers due to thin endometrial lining or canceled cycles. They must not have certain uterine anomalies, be using other proliferation therapies, or have a history of thrombosis. Women with recent unsuccessful transfers before January 1, 2017, are excluded.Check my eligibility
What is being tested?
The study tests if an intrauterine infusion of Platelet Rich Plasma (PRP) can increase the thickness of the endometrium and improve IVF outcomes compared to a normal saline solution in women with infertility issues related to thin endometrial lining.See study design
What are the potential side effects?
Potential side effects may include discomfort at the infusion site, bleeding, infection risk from the procedure itself, and possible allergic reactions to PRP components. However, specific side effects will depend on individual patient responses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during the proliferative phase of the frozen embryo transfer cycle
This trial's timeline: 3 weeks for screening, Varies for treatment, and during the proliferative phase of the frozen embryo transfer cycle for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Endometrial Thickness during frozen embryo transfer
Secondary outcome measures
Sustained implantation rate

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Intervention GroupActive Control1 Intervention
an intrauterine infusion of platelet rich plasma (PRP) will be administered to this group
Group II: Control GroupPlacebo Group1 Intervention
an intrauterine infusion of normal saline will be administered to this group

Find a Location

Who is running the clinical trial?

Reproductive Medicine Associates of New JerseyLead Sponsor
52 Previous Clinical Trials
37,772 Total Patients Enrolled
30 Trials studying Infertility
19,231 Patients Enrolled for Infertility

Media Library

Platelet Rich Plasma Intrauterine infusion (Platelet Rich Plasma) Clinical Trial Eligibility Overview. Trial Name: NCT05538338 — N/A
Infertility Research Study Groups: Intervention Group, Control Group
Infertility Clinical Trial 2023: Platelet Rich Plasma Intrauterine infusion Highlights & Side Effects. Trial Name: NCT05538338 — N/A
Platelet Rich Plasma Intrauterine infusion (Platelet Rich Plasma) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05538338 — N/A
Infertility Patient Testimony for trial: Trial Name: NCT05538338 — N/A
~25 spots leftby Oct 2025